SCYNEXIS Management
Management criteria checks 2/4
SCYNEXIS' CEO is David Angulo, appointed in Jan 2023, has a tenure of 1.25 years. total yearly compensation is $1.17M, comprised of 41.3% salary and 58.7% bonuses, including company stock and options. directly owns 0.24% of the company’s shares, worth $140.12K. The average tenure of the management team and the board of directors is 1.5 years and 8.9 years respectively.
Key information
David Angulo
Chief executive officer
US$1.2m
Total compensation
| CEO salary percentage | 41.3% |
| CEO tenure | 1.3yrs |
| CEO ownership | 0.2% |
| Management average tenure | 1.5yrs |
| Board average tenure | 8.9yrs |
Recent management updates
Recent updates
SCYNEXIS (NASDAQ:SCYX) Seems To Use Debt Rather Sparingly
Apr 04
Scynexis: Update Following Restructuring Of GSK Deal
Apr 02Lacklustre Performance Is Driving SCYNEXIS, Inc.'s (NASDAQ:SCYX) Low P/S
Feb 01Does SCYNEXIS (NASDAQ:SCYX) Have A Healthy Balance Sheet?
Dec 21Little Excitement Around SCYNEXIS, Inc.'s (NASDAQ:SCYX) Revenues As Shares Take 28% Pounding
Sep 26Is SCYNEXIS (NASDAQ:SCYX) Using Too Much Debt?
Aug 17Scynexis: Uninvestible At This Point, Downgrading To A Sell Rating
Aug 26SCYNEXIS Q2 2022 Earnings Preview
Aug 12FDA accepts Scynexis' application to expand label for vaginal yeast infections treatment
Aug 01SCYNEXIS gains after favorable data for antifungal agent in new indication
Jul 19SCYNEXIS, Inc. (NASDAQ:SCYX) Analysts Just Cut Their EPS Forecasts Substantially
Apr 07SCYNEXIS, Inc.: Speculative Buy, Michael Burry Sold, But I Am Buying
Mar 07Some Analysts Just Cut Their SCYNEXIS, Inc. (NASDAQ:SCYX) Estimates
Feb 13Is SCYNEXIS (NASDAQ:SCYX) Using Debt In A Risky Way?
Dec 03Scynexis: Leading The Yeast Infection Treatment Industry
Jul 27Scynexis' Brexafemme qualifies for 10 years of exclusivity for vaginal yeast infections
Jun 09FDA approves SCYNEXIS' BREXAFEMME vaginal yeast infections treatment
Jun 02Is SCYNEXIS (NASDAQ:SCYX) Using Too Much Debt?
Apr 13Market Sentiment Around Loss-Making SCYNEXIS, Inc. (NASDAQ:SCYX)
Mar 15Here's What SCYNEXIS, Inc.'s (NASDAQ:SCYX) Shareholder Ownership Structure Looks Like
Feb 01
Cantor initiates with Overweight rating for Scynexis and Ardelyx on potential drug approval
Jan 06CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | n/a | n/a | US$67m |
| Sep 30 2023 | n/a | n/a | US$72m |
| Jun 30 2023 | n/a | n/a | US$44m |
| Mar 31 2023 | n/a | n/a | -US$91m |
| Dec 31 2022 | US$1m | US$482k | -US$63m |
| Sep 30 2022 | n/a | n/a | -US$78m |
| Jun 30 2022 | n/a | n/a | -US$49m |
| Mar 31 2022 | n/a | n/a | -US$34m |
| Dec 31 2021 | US$987k | US$461k | -US$33m |
| Sep 30 2021 | n/a | n/a | -US$46m |
| Jun 30 2021 | n/a | n/a | -US$45m |
| Mar 31 2021 | n/a | n/a | -US$53m |
| Dec 31 2020 | US$939k | US$447k | -US$55m |
| Sep 30 2020 | n/a | n/a | -US$27m |
| Jun 30 2020 | n/a | n/a | -US$36m |
| Mar 31 2020 | n/a | n/a | -US$38m |
| Dec 31 2019 | US$1m | US$437k | -US$54m |
| Sep 30 2019 | n/a | n/a | -US$37m |
| Jun 30 2019 | n/a | n/a | -US$29m |
| Mar 31 2019 | n/a | n/a | -US$31m |
| Dec 31 2018 | US$769k | US$424k | -US$12m |
| Sep 30 2018 | n/a | n/a | -US$22m |
| Jun 30 2018 | n/a | n/a | -US$31m |
| Mar 31 2018 | n/a | n/a | -US$24m |
| Dec 31 2017 | US$768k | US$412k | -US$25m |
Compensation vs Market: David's total compensation ($USD1.17M) is above average for companies of similar size in the US market ($USD667.11K).
Compensation vs Earnings: David's compensation has been consistent with company performance over the past year.
CEO
David Angulo (58 yo)
1.3yrs
Tenure
US$1,168,835
Compensation
Mr. David Gonzalez Angulo, M. D., had been the Chief Medical Officer at SCYNEXIS, Inc. since June 1, 2015. He is President, Director and Chief Executive Officer of SCYNEXIS, Inc. from January 1, 2023. Mr....
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 1.3yrs | US$1.17m | 0.24% $ 140.1k | |
| Chief Legal Officer & Corporate Secretary | 6.4yrs | US$976.81k | 0.20% $ 117.6k | |
| Chief Financial Officer | 1.5yrs | no data | 0.017% $ 10.1k | |
| Executive Director of Communications | no data | no data | no data | |
| Vice President of Human Resources & Information Technology | no data | no data | no data |
1.5yrs
Average Tenure
58yo
Average Age
Experienced Management: SCYX's management team is not considered experienced ( 1.5 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 1.3yrs | US$1.17m | 0.24% $ 140.1k | |
| Independent Director | 5.3yrs | US$81.86k | 0.013% $ 7.7k | |
| Independent Director | 8.6yrs | US$87.36k | 0.0084% $ 4.9k | |
| Independent Director | 15.3yrs | US$88.36k | 0.0096% $ 5.6k | |
| Independent Chairman of the Board | 9.4yrs | US$111.86k | 0.032% $ 18.6k | |
| Independent Director | 9.2yrs | US$89.36k | 0.011% $ 6.2k | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data |
8.9yrs
Average Tenure
64.5yo
Average Age
Experienced Board: SCYX's board of directors are considered experienced (8.9 years average tenure).